R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Scientist 2 - Pharmacometrician

Quantitative Biology & BiostatisticsUpdated on Nov 11
Full-timeRedwood City, CA, USA$132k - $199k

About the Job

Requirements

  • Ph.D. or equivalent in Statistics, Biostatistics, Mathematics, or a related field.
  • Internship or work experience in the biotechnology or pharmaceutical industry.
  • Track record of applying statistical methods to real-world datasets, including implementing advanced statistical methods.
  • Experience presenting complex concepts and results to specialist and non-specialist audiences in a biotechnology or pharmaceutical setting.
  • Knowledge and hands-on experience with hierarchical models and Bayesian inference, applied to real-world data.
  • Demonstrated experience in statistical modeling, including generalized linear models, survival models, and mixed-effects models.
  • Proficiency in R and/or SAS programming.
  • Must reside in the San Francisco Bay Area.
  • Successful completion of background and employment history verification is required.

Responsibilities

  • Support the pharmacometrics functions in the department as a statistical modeler.
  • Build standard statistical models to conduct exposure-response analysis and drug-drug interaction analysis in clinical studies.
  • Develop and apply state-of-the-art statistical and machine learning methods to identify associations between exposures and responses.
  • Interpret exposure-response results to guide dose-finding decisions.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs